Cardiovascular Renal & Metabolic (CRM) Diseases Market 2025 | Industry Developments, Future Growth, Share & Industry Insights | Johnson & Johnson, Bayer AG, Merck & Co., Inc., Novartis AG, Sanofi, and Amgen Inc

CRM diseases market size reached US$ 298.73 Billion in 2024 from US$ 286.12 Billion in 2023 and is expected to reach US$ 451.87 Billion by 2033, growing at a CAGR of 4.8% during the forecast period 2025-2033

DataM Intelligence unveils its latest report on the "Cardiovascular Renal & Metabolic Diseases Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cardiovascular-renal-metabolic-diseases-market?kb

Key Market Highlights

North America held the largest share of the cardiovascular, renal, and metabolic (CRM) diseases market in 2024, accounting for 44.07% of total revenue.

The Asia-Pacific region emerged as the fastest-growing market, projected to expand at a CAGR of 5.7% during the forecast period.

By disease type, metabolic disorders dominated the market, capturing the largest revenue share of 47.35% in 2024.

List of Top Key Player:

Novo Nordisk, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim International GmbH, Johnson & Johnson, Bayer AG, Merck & Co., Inc., Novartis AG, Sanofi, and Amgen Inc

Latest M&A in CRM Diseases

Roche announced a definitive merger agreement to acquire 89bio Inc. in a deal valued up to $3.5 billion (expected close Q4 2025). 89bio develops pegozafermin, a phase 3 FGF21 analog aimed at treating moderate-to-severe metabolic dysfunction-associated steatohepatitis (MASH), a key cardiometabolic indication.

The acquisition strengthens Roche's cardiovascular, renal, and metabolic (CVRM) portfolio, with potential for combination therapies and pipeline synergy in metabolic diseases.

Pfizer, Novo Nordisk, and other big pharma are also aggressively targeting obesity and metabolic diseases via acquisitions and partnerships in 2025.

Forecast Projection:

The Global Cardiovascular Renal & Metabolic Diseases Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Cardiovascular Renal & Metabolic Diseases Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=cardiovascular-renal-metabolic-diseases-market?kb

Key Segmentation:

By Disease Type: (Cardiovascular Diseases, Renal Diseases, and Metabolic Disorders)

By Treatment Type: (Therapeutics, Devices, and others)

By End-User: (Hospitals, Specialty Clinics, Homecare Settings, Academic and Research Institutes, and Others)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest News & Market Trends

Cardiovascular, renal, and metabolic conditions continue to rise in prevalence, especially in the Medicare fee-for-service population, with healthcare costs markedly higher for these patients.

There is increasing emphasis on comprehensive, multimorbidity-targeted strategies in CRM healthcare.

New clinical data and product launches are focusing on holistic approaches integrating cardiovascular and kidney health with metabolic disease management.

As obesity and diabetes remain public health challenges, investment in innovative CRM therapies continues to surge.

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Cardiovascular Renal & Metabolic Diseases Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cardiovascular-renal-metabolic-diseases-market?kb

Latest FDA Approvals

Recent FDA approvals support kidney and cardiovascular risk reduction in Type 2 diabetes and chronic kidney disease patients (e.g., GLP-1 receptor agonists and SGLT2 inhibitors with expanded indications in early 2025).

Pegozafermin from 89bio is anticipated to file for FDA approval by the end of 2025.

FDA updated quality standards and guidance on combination therapies reflecting the interconnected nature of CRM diseases.

FAQ's

Q1: How large is the Cardiovascular Renal & Metabolic Diseases Market?

Ans: The Cardiovascular Renal & Metabolic Diseases Market size was valued at US$ 298.73 Billion in 2024 and is projected to grow to US$ 451.87 Billion by 2033.

Q2: How quickly is the Cardiovascular Renal & Metabolic Diseases Market expanding?

Ans: The Cardiovascular Renal & Metabolic Diseases Market is forecasted to grow at a CAGR of 4.8% between 2024 and 2031, showing strong growth momentum

Q3: Which regions are dominating the Cardiovascular Renal & Metabolic Diseases Market and which are fastest-growing?

Ans: North America dominating the Cardiovascular Renal & Metabolic Diseases market.

Reimbursement Landscape

Reimbursement frameworks are evolving to recognize the cost burden of CRM diseases, with value-based care models and payer support for innovative therapeutics demonstrating improvements in long-term outcomes.

Medicare spends substantially more on patients with CRM conditions, driving the need for reimbursed therapies that reduce hospitalizations and complications.

Early reimbursement support exists for new GLP-1 receptor agonists and SGLT2 inhibitors, with increasing adoption in treatment guidelines.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/cardiovascular-renal-metabolic-diseases-market?kb

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Relation to Contraceptive Drugs

Combined oral contraceptive pills (COCPs) have known associations with altered metabolic profiles and increased markers of cardiovascular risk (e.g., increased triglycerides, inflammation markers).

Long-term COCP use may influence cardiometabolic risk factors, though discontinuation normalizes many metabolic perturbations.

Research underscores the importance of metabolic monitoring in contraceptive users due to potential cardiovascular side effects, especially in women with pre-existing risk factors.

This comprehensive overview highlights a dynamic CRM therapeutic landscape with major M&A, evolving FDA approvals, growing reimbursement support, and noteworthy cardiometabolic implications linked to contraceptive drug use in 2025

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.